Charles River Laboratories International, Inc. — Q2 2021 Form 10-Q
Reporting period: 13 weeks ended June 26, 2021; six-month comparison is with the six months ended June 27, 2020. The company provides research models and services, drug discovery and safety assessment, and manufacturing solutions to life-sciences customers.
Financial performance
| Metric | Q2 2021 | Q2 2020 | First half 2021 | First half 2020 |
|---|---|---|---|---|
| Revenue | $914.6 million | $682.6 million | $1,739.2 million | $1,389.6 million |
| Operating income | $137.6 million | $76.8 million | $261.3 million | $171.0 million |
| Operating margin | 15.0% | 11.2% | 15.0% | 12.3% |
| Net income attributable to common shareholders | $88.4 million | $67.4 million | $150.0 million | $118.2 million |
| Diluted EPS | $1.72 | $1.34 | $2.93 | $2.36 |
| Cash from operations | Not separately provided | Not separately provided | $356.8 million | $230.9 million |
Q2 revenue increased 34.0%; first-half revenue rose 25.2%. Growth reflected demand across all segments, recovery in RMS from pandemic-related disruption in the prior-year period, acquisitions, and favorable foreign exchange. First-half capital expenditures were $74.5 million; investing cash outflow was $1,092.2 million, primarily for acquisitions.
- Segments, Q2 revenue: RMS $176.7 million, up 51.6%; DSA $540.1 million, up 22.0%; Manufacturing $197.8 million, up 60.2%.
- Segment operating margins, Q2: RMS 24.1% (prior year 3.3%); DSA 19.4% (16.3%); Manufacturing 28.7% (34.8%). Manufacturing margin declined mainly with Cognate-related amortization and higher Microbial Solutions production costs.
- Liquidity and debt at June 26: cash and cash equivalents $223.0 million; total current assets $1,267.9 million and current liabilities $929.6 million. Debt and finance leases totaled $2,754.9 million, including $2,725.4 million of debt before financing costs. The company reported compliance with credit-facility financial covenants.
Material changes and notable items
- Q2 operating income increased 79.2%; first-half operating income increased 52.7%. Higher revenue drove the improvement; first-half net income also reflected debt-extinguishment costs, venture-investment losses, and a higher tax provision.
- Acquisitions included Cognate BioServices for a preliminary $876.1 million net of acquired cash, Retrogenix for $53.1 million net of acquired cash, Distributed Bio acquired in December 2020, and certain DSA assets. The June 28, 2021 Vigene acquisition, for $292.5 million cash plus contingent consideration of up to $57.5 million, occurred after the reporting date.
- First-half financing included $1.0 billion of new 2029 and 2031 senior notes. The company repaid its 2026 notes and remaining term loan and amended its revolving facility, increasing capacity to $3.0 billion and extending maturity to April 2026.
- Q2 effective tax rate was 29.5%, versus 19.4%; first-half rate was 20.6%, versus 15.0%. The company cited enacted tax-law changes and higher nondeductible transaction costs.
Outlook, commentary and risks
The filing provides no specific revenue or earnings guidance. Management said existing funds, expected operating cash flow, and financing access should be sufficient for operations for the foreseeable future. It reported no material change in its assessment of COVID-19 impacts during the first half.
Key disclosed risks include the expanded CDMO business: product and service liability, customer regulatory-approval outcomes, facility compliance and quality, raw-material supply, product-market acceptance, and competition. The company also cited foreign-exchange and floating-rate debt exposure; a 100-basis-point interest-rate increase would raise annual pretax interest expense by an estimated $12.3 million. Pending routine litigation was not expected to have a material adverse effect; tax controversies and audits are ongoing, with no material impact anticipated by management.
Important facts for investors to verify
- How much reported growth reflects underlying demand versus acquisitions and foreign-exchange movements.
- Cognate integration, acquired-business margins, and the effect of acquisition-related amortization and costs.
- Debt levels, floating-rate exposure, covenant headroom, and funding requirements for acquisitions and planned investments.
- Whether CDMO customers obtain regulatory approvals and whether manufacturing quality, supply, and capacity meet requirements.
- Future tax effects, contingent acquisition payments, and resolution of tax matters and other contingencies.